Director Michael D. Cannon filed a Form 4 with the SEC on November 19, 2026, disclosing the acquisition of stock options in Moleculin Biotech, Inc. (NASDAQ:MBRX) on November 17, 2026.
Key Highlights
- Option grant: Michael D. Cannon acquired 4,000 stock options (right to buy) on November 17, 2026.
- Exercise price: The options carry an exercise price of $6.83 per share.
- Expiration date: The options expire on November 17, 2036.
- Vesting condition: Options vest on the earlier of November 17, 2027, or the date of the company's next annual meeting of shareholders, subject to continued Board service.
- Post-transaction holdings: Cannon beneficially owns 4,334 stock options following the reported transaction.
- Board service connection: According to the filing, the options were issued in connection with the reporting person's Board of Director service to the company.
Moleculin Biotech Director Cannon Granted Options Tied to Board Service
According to the Form 4 filed on November 19, 2026, Michael D. Cannon, a director of Moleculin Biotech, Inc. (NASDAQ:MBRX), received a grant of 4,000 stock options on November 17, 2026. The options, classified as the right to buy common stock, carry an exercise price of $6.83 and are set to expire on November 17, 2036. The filing indicates the transaction code as "A," reflecting an acquisition of derivative securities.
The filing states that the options "vest on the earlier of November 17, 2027 or the date of the Company's next annual meeting of shareholders, subject to the grantee's continued service on the Company's Board of Directors on the vesting date." The grant was made directly and is described as being issued in connection with Cannon's Board of Director service to the company. No shares of non-derivative common stock were reported as acquired or disposed of in this filing.
Following the reported transaction, Cannon beneficially owns a total of 4,334 stock options in Moleculin Biotech on a direct basis. The Form 4 was signed by Jonathan Foster by Power of Attorney and dated November 19, 2026.
What Was Disclosed
Moleculin Biotech director Michael D. Cannon disclosed the acquisition of 4,000 stock options at an exercise price of $6.83, expiring November 17, 2036, with vesting tied to continued Board service. Total beneficial ownership of options following the transaction stands at 4,334.


Please wait processing your request...